A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma.
Li CC, Bender B, Wilkins J, Li F, Turner DC, Wang B, Deng R, Vadhavkar S, Li Z, Kwan A, Huang H, Peng K, Penuel E, Huw LY, Chanu P, Li C, Yin S, Wei MC.
Li CC, et al.
Clin Pharmacol Ther. 2024 Sep 27. doi: 10.1002/cpt.3445. Online ahead of print.
Clin Pharmacol Ther. 2024.
PMID: 39328022